Market research
INO Inovio Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 129M
- P/E ratio
- Not available
- Analyst target
- 3.1667
- Dividend yield
- Not available
- Beta
- 1.51
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US45773H4092
- Market cap
- 129M
- P/E ratio
- Not available
- Analyst target
- 3.1667
- Dividend yield
- Not available
- Beta
- 1.51
About
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the INO discussion.
5 years, 4 months ago
Inovio Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 12.2% below its 200 day moving average.
From a valuation standpoint, the stock is 85.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 191.0.
Inovio Pharmaceuticals, Inc's total revenue rose by 1896.7% to $6M since the same quarter in the previous year.
Its net income has increased by 35.4% to $-24M since the same quarter in the previous year.
Finally, its free cash flow fell by 276.7% to $-52M since the same quarter in the previous year.
Based on the above factors, Inovio Pharmaceuticals, Inc gets an overall score of 3/5.